Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alcon Research
This study consisted of two phases, a Screening/Eligibility Phase and a Treatment Phase. Both phases required the patient to complete an overnight stay.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of either open-angle glaucoma or ocular hypertension in both eyes.
Willing and able to attend all study-related visits and be housed overnight at clinical site for the study assessments.
Must sign an Informed Consent form.
You may not be if
Women of childbearing potential if pregnant, breastfeeding, or not using adequate birth control.
Severe central visual field loss in either eye.
Chronic, recurrent or severe inflammatory eye disease.
Ocular trauma or ocular surgery within the past 6 months.
Ocular infection or ocular inflammation within the past 3 months.
Clinically significant or progressive retinal disease.
Other ocular pathology, including severe dry eye, that may in the opinion of the investigator preclude the administration of study medication.
Any other conditions including severe illness which would make the patient, in the opinion of the Investigator, unsuitable for the study.
Any medical condition that would preclude the safe administration of a topical beta-blocker.
Cannot safely discontinue all glucocorticoids administered by any route.
Clareo Health | Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
